Authors
Loading...
Phase I trial determines maximum tolerated dose of 90Y-anti-CD25 Mab in relapsed acute leukemia, suggesting potential for improved outcomes.
Wong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: